| Literature DB >> 31877702 |
Cristiano Capurso1, Francesco Bellanti1, Aurelio Lo Buglio1, Gianluigi Vendemiale1.
Abstract
The aging population is rapidly increasing all over the world. This results in significant implications for the planning and provision of health and social care. Aging is physiologically characterized by a decrease in lean mass, bone mineral density and, to a lesser extent, fat mass. The onset of sarcopenia leads to weakness and a further decrease in physical activity. An insufficient protein intake, which we often observe in patients of advanced age, certainly accelerates the progression of sarcopenia. In addition, many other factors (e.g., insulin resistance, impaired protein digestion and absorption of amino acids) reduce the stimulation of muscle protein synthesis in the elderly, even if the protein intake is adequate. Inadequate intake of foods can also cause micronutrient deficiencies that contribute to the development of frailty. We know that a healthy eating style in middle age predisposes to so-called "healthy and successful" aging, which is the condition of the absence of serious chronic diseases or of an important decline in cognitive or physical functions, or mental health. The Mediterranean diet is recognized to be a "healthy food" dietary pattern; high adherence to this dietary pattern is associated with a lower incidence of chronic diseases and lower physical impairment in old age. The aim of our review was to analyze observational studies (cohort and case-control studies) that investigated the effects of following a healthy diet, and especially the effect of adherence to a Mediterranean diet (MD), on the progression of aging and on onset of frailty.Entities:
Keywords: Mediterranean diet; aging; frailty; sarcopenia
Mesh:
Year: 2019 PMID: 31877702 PMCID: PMC7019245 DOI: 10.3390/nu12010035
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Fried’s criteria of frailty (line 69).
Figure 2The Canadian Study of Health and Aging (CSHA) Clinical Frailty Scale by Rockwood.
Figure 3The vicious circle of frailty (line 92).
Mediterranean Diet adherence and risk of mortality.
| Author and Year of Publication | Study Design | Sample Size | Risk of Mortality |
|---|---|---|---|
| Trichopoulou, 2003, [ | Population-based, prospective study | 8895 men and 13,148 women | Death from any cause: |
| Estruch, 2013, [ | Parallel-group, multicentre, randomized | 1050 men and 1493 women with MD with EVOO | Myocardial infarction, stroke, and death from cardiovascular causes: |
| Estruch, 2018, [ | Parallel-group, multicentre, randomized | 1050 men and 1493 women with MD with EVOO | Myocardial infarction: |
| Sofi, 2008, [ | Meta-analysis of prospective cohort studies | 1,574,299 subjects from 12 studies | Mortality from cardiovascular diseases: |
| Sofi, 2010, [ | Meta-analysis of prospective cohort studies | 508,393 subjects from 7 studies | Mortality from cardiovascular diseases: |
| Kromhout, 2018, [ | Prospective Cohort Study | 12,763 subjects from 16 cohorts of the Seven Countries Study | Mortality from cardiovascular diseases: |
Poly-unsaturated fatty acids intake and mortality.
| Author and Year of Publication | Study Design | Sample Size | Risk of Mortality |
|---|---|---|---|
| GISSI Prevention trial, 1999, [ | Prospective Cohort Study | 8496 cases and 2828 controls from a cohort of 11,324 subjects | Death, non-fatal MI, and non-fatal stroke in two-way analysis: |
| Yokoyama, 2007, [ | Prospective Randomised Open-Label Cohort Study | 9326 EPA treatments and 9319 controls from a cohort of 18,645 subjects | Incidence of coronary events in the total study population: |
| Kromhout, 2010, [ | Prospective Multi-centre, double-blind trial: n−3 fatty acids EPA and DHA and plant-derived ALA vs. placebo | 1212 subjects randomized to receive EPA–DHA and ALA; | Major cardiovascular events: |
| Einvik, 2010, [ | Interventional Clinical Trial | 563 Norwegian men randomized to a 3-year clinical trial of diet with n-3 PUFA supplementation vs. placebo (corn oil) | Mortality from any cause: |
| Bosch, 2012, [ | Prospective multi-centre, double-blind trial: n−3 fatty acids vs. placebo | 6281 subjects randomized to receive n−3 fatty acids; | Death from cardiovascular causes: |
| Rauch, 2010, [ | Prospective randomized, placebo-controlled, double-blind, multicentre trial | 1919 subjects randomized to receive n−3 fatty acids; | Sudden cardiac death: |
| Galan, 2010, [ | Prospective randomized, placebo-controlled, double-blind trial | 620 subjects randomized to receive B vitamins + omega 3 | Non-fatal myocardial infarction, stroke, or death from cardiovascular disease: |
| Bonds, 2014, [ | 2 × 2 factorial-designed randomized clinical trial | 1079 subjects randomized to receive lutein + zeaxanthin and DHA + EPA; | Time to First Cardiovascular Disease Mortality/Morbidity Event: |
| Deepak, 2019, [ | Multicentre, randomized, double-blind, placebo-controlled trial | 4089 subjects randomized to receive 2 g of Icosapent Ethyl twice daily; | Cardiovascular death, nonfatal myocardial infarction, nonfatal |
| Bucher, 2002, [ | Meta-analysis from 11 case-control studies | 7951 patients in the treatment groups and 7855 patients in the control groups | Nonfatal myocardial infarction: |
| Rizos, 2012, [ | Meta-analysis from 20 case-control studies | 34,388 patients in the treatment groups and 34,292 patients in the control groups | All-cause mortality: |
| Kwak, 2012, [ | Meta-analysis from 14 placebo-control trials | 10,226 patients in the treatment groups and 10,259 patients in the control groups | Overall cardiovascular events: |
| Agency for Healthcare Research and Quality, 2016, [ | Meta-analysis from 61 randomized controlled trials and 37 longitudinal observational | No available data about sample sizes of cohorts examined | All-cause death: |
| Zhang, 2018, [ | Prospective cohort study | Total and cause-specific | All-cause death: |
Figure 4Effect of caloric restriction on aging and on the development of frailty (line 433).
Mediterranean diet components and healthy aging.
| Author and Year of Publication | Study Design | Sample Size | Risk of Mortality |
|---|---|---|---|
| Trichopoulou, 1995, [ | Prospective cohort study | 91 men and 91women | Mortality Rate: |
| Britton, 2008, [ | Longitudinal cohort study | 4140 men and 1823 women | Likelihood of Successful Aging for men: |
| Akbaraly, 2013, [ | Longitudinal cohort study | 3775 men and 1575 women | Ideal Aging with Healthy-foods diet: |
| Samieri, 2013, [ | Cross-sectional observational study | 1171 “Healthy agers” vs. 9499 “Usual agers” | Healthy aging and component of healthy aging, according to Alternative Healthy Eating Index-2010: |
| Trichopoulou, 2005, [ | Multicentre, prospective cohort study | 24,545 men and 50,062 women from the EPIC-elderly cohort | Mortality ratios (MR) for all countries: |
| Shi, 2015, [ | Longitudinal cohort study | 3567 men and 5392 women from the Chinese Longitudinal Healthy Longevity Survey (CLHLS) | Hazard ratios for all-cause mortality: |
Mediterranean diet pattern, muscle mass and muscle strength.
| Author and Year of Publication | Study Design | Sample Size | Muscle Mass and Muscle Strength |
|---|---|---|---|
| Kelaiditi, 2016, [ | Cross-sectional study | 2570 women from the Twins UK study | Fat-free mass (%): |
| Huang, 2016, [ | Cross-sectional study | 327 community-dwelling elderly people | Odds ratios for total protein and vegetable protein density for Low Muscle Mass (LMM): |
| Ter Borg, 2016, [ | Cross-sectional study | 227 community-dwelling adults aged over 65 years from the Maastricht Sarcopenia Study | Mean(SD) of daily dietary and supplement intake of nutrients for sarcopenic vs. nonsarcopenic subjects: |
| Verlaan, 2017, [ | Matched case-control observational study | 66 sarcopenic older adults vs. 66 non-sarcopenic older adults from the PROVIDE Study | Mean (SD) of daily dietary nutrient intakes for sarcopenic vs. nonsarcopenic subjects: |
| Barrea, 2019, [ | Cross-sectional observational study | 84 not hospitalized elderly women from the PERSSILAA project | Daily nutrients (SD, range) intake of participants according the HGS cut-point: |
Mediterranean diet components and frailty.
| Author and Year of Publication | Study Design | Sample Size | Risk of Frailty |
|---|---|---|---|
| Milaneschi, 2011, [ | Prospective population-based study | 935 community-living subjects aged over 65 years from the InCHIANTI Study cohort | Adjusted odds of developing mobility disability: |
| Bollwein, 2013, [ | Cross-sectional study | 192 community-dwelling volunteers aged over 75 years | Odds Ratio for Frailty: |
| Talegawkar, 2012, [ | Prospective population-based study | 690 community-living subjects aged over 65 years from the InCHIANTI Study cohort | Odds Ratio for Frailty: |
| Luz, 2015, [ | Prospective cohort study | 1872 non-institutionalized subjects aged over 60 years from the Seniors-ENRICA cohort Study | Odds Ratio for Frailty: |
| Rahi, 2017, [ | Population-based prospective cohort study | 560 non-institutionalized subjects aged over 65 years from the cohort of Three-City-Bordeaux Study | Odds Ratio for Frailty: |
| Veronese, 2017, [ | Population-based prospective cohort study | 1857 men and 2564 women from the The Osteoarthritis Initiative cohort Study | Odds Ratio for Frailty: |
Figure 5The course and consequences of frailty (line 686).